Cantoni Therapeutics Secures Funding to Advance Novel NNMT Inhibitor for Obesity Treatment
Key Insights
Cantoni Therapeutics (search) closed additional financing from multiple investors to advance its lead NNMT (search) inhibitor into IND-enabling studies for obesity (search) treatment.
The company's small molecule inhibitors (search) target nicotinamide N-methyltransferase (search) (NNMT (search)), offering a differentiated mechanism from current incretin-based obesity (search) therapies.
Preclinical studies demonstrated the ability to reduce fat mass without impacting lean mass through increased energy expenditure rather than reduced intake.
Cantoni Therapeutics (search), a biotech company spun out from Leiden University (search), announced the closing of additional financing to advance its lead nicotinamide N-methyltransferase (search) (NNMT (search)) inhibitor into IND-enabling studies for obesity (search) and its comorbidities. The funding round included participation from Brabant Development Agency (search) (BOM) and an angel investor, joining lead investor Libertatis Ergo Holding (search) (LEH), with additional support from Brabant Startup Fund (search) (BSF).
The Netherlands-based company is developing best-in-class small molecule inhibitors (search) targeting NNMT (search), a metabolic enzyme highly expressed in metabolic tissues including liver, adipose tissue, and muscle. In preclinical studies, Cantoni's NNMT inhibitors (search) demonstrated the ability to reduce fat mass without negatively impacting lean mass, while improving metabolic health through increased energy expenditure.
Novel Mechanism Differentiates from Current Therapies
Cantoni's approach represents a significant departure from existing obesity (search) treatments. According to Floris Hamel, Investment Manager at BOM, "Cantoni's NNMT (search) inhibition mechanism of action is highly differentiated from the currently approved incretin-based therapies (search) and has the potential to become a new treatment option for obesity and its comorbidities."
The company's preclinical data in diet-induced obese mice showed that NNMT inhibitors (search) induce fat mass reduction and improved metabolic health through increased energy expenditure rather than reduced energy intake. This mechanism distinguishes it from current obesity (search) medications that primarily work by suppressing appetite or reducing nutrient absorption.
Novo Nordisk Validates Target with Research Grant
In addition to the equity and loan financing, Cantoni was awarded a validatioNN grant from Novo Nordisk to support disease-relevant translational research on NNMT (search). The grant will fund research into the mode of action of NNMT inhibition, providing validation from a leading pharmaceutical company in the metabolic disease space.
"This combined equity and loan financing, and the research grant from Novo Nordisk will help significantly as we progress towards our ultimate goal to validate NNMT (search) as a novel target for obesity (search) and its comorbidities in the clinic," said Annegret Van der Aa, PhD, Chief Executive Officer and Executive Director at Cantoni.
Broader Therapeutic Potential
NNMT (search) represents an attractive drug target for cardiometabolic diseases, with elevated NNMT levels correlated with obesity (search), type 2 diabetes (search), and cardiovascular diseases (search). Beyond obesity, the metabolic enzyme presents opportunities in other therapeutic areas, with research describing NNMT's role in chronic kidney disease (search) development and cancer (search) progression.
Gerard Spanbroek, Managing Director at BSF, expressed confidence in the platform's potential: "We believe Cantoni's small molecule NNMT inhibitors (search) could be a game changer for treatment of obesity (search) and other indications."
Company Background and Leadership
Cantoni was founded in December 2022 as a spinout from Leiden University (search) by scientific founders Professor Nathaniel Martin and Dr. Matthijs van Haren. The founding scientists bring extensive experience in the discovery and optimization of small molecule drug candidates, with an established track record in drug development.
The company's focus on NNMT (search) inhibition builds on scientific understanding of this metabolic enzyme's role in disease pathogenesis. With the new funding and Novo Nordisk's research support, Cantoni is positioned to advance its lead asset toward clinical development, potentially offering a new therapeutic approach for patients with obesity (search) and related metabolic disorders.